Internal reviews at Penn State Health repeatedly documented serious lapses in patient care and a “toxic culture” under the direction of Dr. Raymond Hohl, the highly-paid director of the Penn State Cancer Institute, according to a Spotlight PA investigation.
Despite multiple reports detailing sloppy recordkeeping, accidental chemotherapy overdoses, treatment delays for at least 10 patients, and mass staff resignations, Hohl remained in his leadership role. Penn State recruited Hohl almost a decade ago to secure the prestigious National Cancer Institute designation, a goal an internal December 2022 report found the institute was “significantly behind” on, despite a $410 million investment.
Penn State Health declined to make Hohl available for comment but stated the institute operates at a “world-class” level and has since made “substantial adjustments.”
Comments